6533b870fe1ef96bd12cfb60
RESEARCH PRODUCT
Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.
Andrea CorbaciogluFabian J. TheisD. HaaseGerhard HeldMichael HeuserThomas KindlerPeter BrossartR.f. SchlenkWalter FiedlerHartmut DöhnerPeter PaschkaLars BullingerMohammed WattadDavid NachbaurDaniela WeberJürgen KrauterArnold GanserFelicitas TholBrigitte SchlegelbergerHeinz-august HorstGudrun GöhringClaus-henning KöhneKatharina GötzeK DöhnerUlrich GermingMichael LübbertHelmut R. SalihVerena I. GaidzikMark Ringhoffersubject
AdultMaleCancer Researchmedicine.medical_specialtyMyeloidAdolescentmedicine.disease_causeCohort Studies03 medical and health sciencesYoung Adult0302 clinical medicinehemic and lymphatic diseasesInternal medicineCEBPAmedicineHumansneoplasmsAgedMutationHematologybusiness.industryMyeloid leukemiaHematologyMiddle Agedmedicine.diseaseLymphomaGATA2 Transcription FactorHaematopoiesisLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureOncology030220 oncology & carcinogenesisMutationCancer researchCCAAT-Enhancer-Binding ProteinsFemalebusiness030215 immunologydescription
Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group
year | journal | country | edition | language |
---|---|---|---|---|
2016-11-03 | Leukemia |